# Breakthru Medicine

Source: https://onco.cc/companies/breakthru-medicine/  
OnCo record `breakthru-medicine` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Breakthru Medicine is a Phoenix cancer drug company working on small molecules, a molecular glue platform and new drug payloads for antibody-drug conjugates. It came out of stealth in January 2026 and aims to start its first clinical trial in early 2027.

## Summary

Breakthru Medicine, based in Phoenix, Arizona, emerged from stealth on 29 January 2026 with a USD 60 million Series A, following an undisclosed seed round. It describes a patient-first, tumour-agnostic targeting approach across multiple modalities, including small molecules, next-generation antibody-drug conjugate payloads and an emerging molecular glue platform whose details it has not disclosed. The company was founded by Steve Potts (chief executive), Mark Mulvihill (chief scientific officer) and Brian Barnett; its board and investors include Dave Morehead, Fred Eshelman of Eshelman Ventures, and Mark Gergen. Its website states that its lead programme is targeting clinical trials in early 2027.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Phoenix, AZ
- Type: biotech
- Website: https://www.breakthrumed.com/

## Notes

- Founding year not stated. No programme, target or cancer has been disclosed. The website's figures of 12 FDA approvals and 8 Breakthrough Therapy designations appear under a leadership heading and appear to describe the team's prior careers, not the company's own medicines; they are not repeated here.

## Sources

- Official website: https://www.breakthrumed.com/
- Launch release, January 2026: https://www.breakthrumed.com/post/breakthru-medicine-emerges-from-stealth-with-60m-series-a-for-cancer-drug-development

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Molecular glue discovery platforms](https://onco.cc/technologies/molecular-glue-platforms/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)

---
JSON: https://onco.cc/api/v1/entities/breakthru-medicine.json